Detalles de la búsqueda
1.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol
; 100(9): 2325-2337, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33970288
2.
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Ann Surg Oncol
; 22(4): 1153-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25358667
3.
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Support Care Cancer
; 21(10): 2845-51, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23748485
4.
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Oncology
; 83(3): 135-40, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22814309
5.
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 20(1): 8-17.e16, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31722839
6.
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.
Expert Rev Hematol
; 13(4): 421-433, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32148109
7.
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
Am Health Drug Benefits
; 12(7): 333-342, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32055281
8.
Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.
Am J Manag Care
; 25(3): e66-e70, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30875173
9.
Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Expert Rev Hematol
; 12(1): 71-79, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30513016
10.
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care.
Leuk Lymphoma
; 60(1): 49-59, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29932781
11.
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.
Pharmacoecon Open
; 3(2): 237-245, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30324565
12.
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Leuk Res
; 78: 45-51, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30716655
13.
Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting: A Matched-Claims Analysis of Patients With Breast, Colorectal, and Lung Cancers.
J Oncol Pract
; : JOP1700040, 2018 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30379608
14.
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies.
J Geriatr Oncol
; 9(2): 138-144, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29056336
15.
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
Leuk Res
; 71: 27-33, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29944984
16.
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Clin Lymphoma Myeloma Leuk
; 18(2): 152-160, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29395837
17.
Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
J Oncol Pract
; 13(2): e139-e151, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28029298
18.
A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ther Adv Med Oncol
; 9(2): 75-82, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28203300
19.
Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
Med Oncol
; 33(1): 4, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26696390
20.
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Expert Rev Anticancer Ther
; 13(8): 919-36, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23984894